 |
Indication & Dosage |
| |
| |
| Oral |
| MENORRHAGIA |
| Adult:
10-25 mg daily continuously for 4-9 mth. As acetate: 5-15 mg daily, start at 5 mg daily and increase by 2.5 mg at 14 day intervals. Take continuously for 4-9 mth. |
| |
| Oral |
| ENDOMETRIOSIS |
| Adult:
10-25 mg daily continuously for 4-9 mth. As acetate: 5-15 mg daily, start at 5 mg daily and increase by 2.5 mg at 14 day intervals. Take continuously for 4-9 mth. |
| |
| Oral |
| CONTRACEPTION |
| Adult:
0.35 mg daily, or 0.5-1 mg daily when combined with oestrogen. As acetate: 0.6 mg daily, or 1-1.5 mg daily when combined with oestrogen. |
| |
| Oral |
| PROGESTOGEN COMPONENT OF MENOPAUSAL HRT |
| Adult:
0.7 mg as a continuous daily dose. As acetate: 1 mg daily for 10-12 days of a 28-day cycle. |
| |
| Oral |
| PREMENSTRUAL SYNDROME |
| Adult:
5 mg tid on days 16-25 of cycle. |
| |
| Oral |
| DISSEMINATED BREAST CARCINOMA |
| Adult:
40 mg daily increasing to 60 mg if no regression is noted. |
| |
| Intramuscular |
| CONTRACEPTION |
| Adult:
As enantate: 200 mg every 8 wk. |
| |
| Transdermal |
| PROGESTOGEN COMPONENT OF MENOPAUSAL HRT |
| Adult:
10-15 mg daily in a cyclical regimen. Usual dose: 5 mg tid for 10 days as primary treatment, subsequently 5 mg bid on days 19-26 of cycle to prevent recurrence. As acetate: 2.5-10 mg daily in a cyclical regimen, beginning during the assumed latter half of the cycle |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
Hypertension; CVS disease; hepatic impairment; epilepsy; lactation; new onset of migraine-type headache; asthma; renal impairment; history of clinical depression. |
| |
|
| Adverse Drug Reactions |
Mental depression, cholestatic jaundice, porphyria, epilepsy, migraine, headache, breast discomfort, dizziness, nausea and vomiting, changes in libido, appetite and weight, breakthrough bleeding, changes in menstrual flow, amenorrhoea, oedema, rash, melasma or cholasma, acne, urticaria, abnormal LFTs, moodswings, insomnia, thrombotic and thromoembolic events, optic neuritis, altered lipid profile. |
| |
|
| Interactions |
Concentration may be reduced by CYP450 inducers (e.g. phenobarbital, phenytoin, carbamazepine, rifampicin, rifabutin, nevirapine, efavirenz, tetracyclines, ampicillin, oxacillin, co-trimoxazole) and ritonavir, nelfinavir (usually inhibitors of CYP450 but have inducing properties when used with steroid hormones). May cause additive fluid retention with NSAIDs, vasodilators. Adjustment in antidiabetic, thyroid hormone and anticoagulant therapy may be required. |
| |
|
|
|
